Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia Poster Population K-PD Modeling of Plozasiran (ARO-APOC3), a GalNAc-siRNA Conjugate, for the Potential Treatment of Atherosclerotic Cardiovascular Disease (ASCVD) in Patients with Mixed Hyperlipidemia CertaraNovember 22, 2024
Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites Poster Integrated Population Pharmacokinetic Model of Bemnifosbuvir and Metabolites CertaraNovember 22, 2024
Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) Poster Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis (AG10) CertaraNovember 22, 2024
Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen Poster Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen CertaraNovember 22, 2024
Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials Poster Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials CertaraNovember 22, 2024
Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus Poster Quantitative Systems Pharmacology model for combined targeting of BAFF and CD40 pathways in systemic lupus erythematosus CertaraNovember 22, 2024
Population pharmacokinetic modeling of niraparib to assess different absorption models Poster Population pharmacokinetic modeling of niraparib to assess different absorption models CertaraNovember 22, 2024
Why Clinical Pharmacology & Pharmacometrics Should Collaborate Blog Why Clinical Pharmacology & Pharmacometrics Should Collaborate A symbiosis between a modeler and a trialist is often required to develop a model-informed…CertaraNovember 8, 2024
A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population Publication A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population CertaraNovember 7, 2024
JSCPT 2025 – The 46th Annual Scientific Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics Conference JSCPT 2025 – The 46th Annual Scientific Meeting of The Japanese Society of Clinical Pharmacology and Therapeutics We’re excited to participate in JSCPT 2025 in Tokyo, The 46th Annual Scientific Meeting of…CertaraOctober 31, 2024